This is a multicenter, non-interventional and prospective real-world study to evaluate the efficacy and safety of Duvelisib capsules in patients with non-Hodgkin's lymphoma.
To participate in the study voluntarily and sign the informed consent (ICF), with good compliance and cooperative visits;
Patients must be ≥ 18 years of age (Based on the date of signing the informed Consent (ICF));
Follicular lymphoma (FL);
Chronic lymphocytic leukemia/small lymphocytic lymphoma or Richter syndrome (CLL/SLL or RS);
Female subjects who are pregnant or breastfeeding;
Estimated lifetime is less than 3 months;
In the investigator's judgment, patients who require but are unable to receive prophylactic treatment for Pneumocystis or herpes simplex virus (HSV) prior to trial drug treatment;
History or concurrent condition of interstitial lung disease of any severity and/or severely impaired lung function;
Population who have been diagnosed with non-Hodgkin's lymphoma that is relapsed or refractory, including but not limited to the following subtypes : a) Follicular lymphoma(FL); b) Chronic lymphocytic leukemia/small lymphocytic lymphoma or Richter syndrome(CLL/SLL or RS); c) Marginal zone lymphoma(MZL); d) Peripheral T-cell lymphoma(PTCL); e) Diffuse large B-cell lymphoma(DLBCL).
Cohort
Prospective
Duvelisib
DrugThis is a real-word. The treatment options are individualized according to the diagnosis and treatment experience of doctors in each center, diagnosis and treatment specifications and individual conditions of patients.
Adverse events (AE)
The safety of the drug was evaluated by NCI-CTC AE 5.0 standard.
Overall Response Rate (ORR)
Defined as the best response of complete response/remission (CR) or partial response/remission (PR).
Duration of remission (DOR)
Time from reaching CR or PR for the first time to disease progression.
Progression-Free-Survival (PFS)
From date of inclusion to date of progression, relapse, or death from any cause.
Overall survival (OS)
From the date of inclusion to date of death, irrespective of cause.
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
